David Brennan, CEO of AstraZeneca UK Limited (AZN), was passionate about bringing new medicines to patients. But the industry converting one who showed less patent protection, more competition from generic drugs, more stringent government regulations, reduced productivity in R & D. Strategy? Build a pipeline to the new prescription drugs that were unique enough to provide differentiated benefits for patients, the development of business in the world, streamline the organization and efficiency, as well as a culture of courage, creativity and cooperation. Will the company be able to provide a stable and consistent pipeline of new products at a lower price, most likely, with fewer people? How can a company an average of two new products to the market every year? What areas of R & D company to invest, and that would be R & D conversion look like? "Hide
by Scott Snell, Gerry Yemen Source: Darden School of Business 25 pages. Publication Date: August 16, 2012. Prod. #: UV6507-PDF-ENG
Related Case Solutions & Analyses:
NTT DoCoMo (TM): Value Innovation at DoCoMo
Googles Android: Will It Shake Up the Wireless Industry in 2009 and Beyond
American National Red Cross (B)
Lincoln Industries
Saras Options
Fsas: Fujitsu Support and Service Inc.
CASE ANALYSIS: MANAGING CREATIVITY AT SHANGHAI TANG
Sunac’s Acquisition of Greentown in the Chinese Real Estate Market (A)
TRIP ADVISOR
The search for Property- Institutional Investment in Real Estate
